Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07459660 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
A Phase 2 study, sponsored by MapLight Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
NCT07459660 is a Phase 2 study that is actively recruiting participants, run by MapLight Therapeutics. The registered enrollment target is 210 participants.
The verdict
NCT07459660, a Phase 2 study, is actively recruiting participants, sponsored by MapLight Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
Study Summary
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
Interventions
- DRUG ML-007C-MA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-03-25 |
| Est. Completion | 2029-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07459660
The ClinicalTrials.gov registry entry for NCT07459660 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MapLight Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ML-007C-MA is the first listed.
NCT07459660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07459660 about?
NCT07459660 is a clinical study titled "An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis". ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
What is the current status of trial NCT07459660?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2026-03-25. Estimated completion is 2029-03.
What interventions are being tested in trial NCT07459660?
The interventions under investigation include: ML-007C-MA (DRUG).
Who is sponsoring clinical trial NCT07459660?
This trial is sponsored by MapLight Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.